NDAORALTABLETPriority Review
Approved
Apr 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PEGANONE (ethotoin) is an oral aromatic antiepileptic drug approved in 1957 for seizure management. It belongs to the hydantoin class of anticonvulsants used to control generalized tonic-clonic and complex partial seizures. The exact mechanism involves stabilization of neuronal membranes and modulation of sodium channels.
LOE Approaching
With LOE approaching and minimal linked job openings, this is a legacy product with declining commercial infrastructure and limited team expansion opportunity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PEGANONE offers limited career growth due to zero linked job openings and approaching LOE, positioning roles as maintenance-focused rather than growth-oriented. Career development is constrained to legacy product management, compliance, and field support without expansion into innovation or new market development.
Product Manager (Legacy)Field Sales Representative
Worked on PEGANONE at Recordati? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.